Search Results

21 - 30 of 91 items :

  • pharmacokinetics x
  • Internal Medicine x
Clear All
Review of a New Multimodal Antidepressant Vortioxetine

treatment of major depressive disorder. J Pharmacol Exp. Ther. 2012; 340 (3): 666-675. 7. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012; 40 (7): 1357-1365. 8. Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013; 33: 727-736. 9

Open access
Vitamin C dosing during continuous renal replacement therapy: The last word is not said!

To the editor Pharmacokinetic and dose-response data suggest a vitamin C (vit C) dose largely exceeding 3 g daily in critically ill patients. We recently proposed higher vit C dosing in cardiac arrest patients who require continuous renal replacement therapy (CRRT).[ 1 ] In a reaction, Spoelstra-de Man et al . rebutted that increasing the vit C dose above 2 g/day during continuous veno-venous hemofiltration (CVVH) was unnecessary when normal plasma vit C concentrations are targeted. They based their standpoint on calculating less vit C removal during CVVH

Open access
Efficacy and Tolerability of Eight Antimicrobial Regimens in the Outpatient Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease

outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40(1):17-27. 31. Siempos II, Dimopoulos G, Korbila JP, Manta K, Falagas ME. Macrolides, quinolones and amoxicillin/clavulonate for chronic bronchitis: meta-analysis. Eur Respir J. 2007; 29 (6): 1127-1137. 32. Perry CM, Brogden RN. Cefuroxime Axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996; 52 (1): 125-156. 33. Destache CJ, Dewan N, O’Donohue WJ, Campbell JC, Anqelillo VA. Clinical and

Open access
Qualitative Histological Analysis of Adrenal Cortex Following Application of Medroxyprogesterone Acetate

medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab. 1976;42(5):912-7. doi:10.1210/jcem-42-5-912 PMID:178684. Blossey HC, Wander HE, Koebberling J, Nagel GA. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer. 1984;54(6 Suppl):1208-15. doi:10.1002/1097-0142(19840915)54:1+<1208::AID-CNCR2820541319>3.0.CO;2-K PMID:6088020. van Veelen H, Willemse PH, Sleijfer DT, van der Ploeg E, Sluiter WJ, Doorenbos H. Mechanism

Open access
Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study

and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2:471-8. [15] Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9:327-37. [16] Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis and targeted

Open access
Distribution of CYP2C9 and VKORC1 Gene Polymorphisms in Healthy Macedonian Male Population

genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004; 76(1):18-26. 21. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.Pharmacogenomics. 2011; 12 (12):1663-70. 22. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and

Open access
Apnea in preterm newborns: determinants, pathophysiology, effects on cardiovascular parameters and treatment

Respiratory Care. Springer Sience + Business Media, LLC 2012., p.251-252. ISBN:987-1-4614-2154-2. 59. Dobson NR, Hunt CE. Pharmacology review: Caffeine use in neonates: Indications, pharmacokinetics, clinical effects, outcomes. Neoreviews, 2013; 14: e540-e550. 60. Aranda JV, Beharry K, Valencia GB, Natarajan G, Davis J. Caffeine impact on neonatal morbidities. The Journal of Maternal-Fetal and Neonatal Medicine, 2010; 23(S3): 20-23. 61. Patel RM, Leong T, Carlton P, Vyas-Read S. Early caffeine therapy and clinical outcomes

Open access
Potential Effects of Bee Honey and Propolis Against the Toxicity of Ochratoxin A in Rats

. Effect of a necrogenic dose of diethylnitrosamine on vitamin E-deficient and vitamin E-supplemented rats. Food Chem Toxicol. 1998;36(11):929-35. doi:10.1016/S0278-6915(98)00043-X PMID:9771554 Rowland M, Tozer TN. In Clinical Pharmacokinetics: Concepts and Applications, 3 rd ed. Lea, Febiger: Philadelphia , 1989:148-160. Gheldof N, Engeseth NJ. Antioxidant capacity of honey from various floral sources based on the determination of oxygen radical absorbance capacity and inhibition of lipoprotein oxidation in human

Open access
Cannabis and alcohol in road traffic: an overview

. Developing limits for driving under cannabis. Addiction 2007; 102: 1910–7. 23. Berghaus G, Sticht G, Grellner E, Lenz D, Naumann T, Wiesenmüller S. Meta analysis of empirical studies concerning the effects of medicines and illegal drugs including pharmacokinetics on safe driving. DRUID Deliverable D 1.1.2b. Würzburg, Germany: University of Würzburg; 2010. 24. Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004; 23: 319–344. 25. Berghaus G, Sheer N, Schmidt P

Open access
Biosimilar medicines and patient registries – expectations, limitations, and opportunities

Conference Paper: Annual European Congress of Rheumatology , 2017. 42. Kim W, Buske C, Oqura M, Jurczak W, Sancho J, Zhavrid E, Kim J, Hernandez-Rivas J, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak L, Lee S, Lee S, Bae Y, Coiffier B. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017; 4(8): e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14

Open access